RET and medullary thyroid gland carcinoma: Broad-based tyrosine kinase inhibitors (TKI) such as cabozantinib are approved for the treatment of RET mutations (base substitutions) in medullary thyroid cancers occurring both in sporadic forms and as a component of the MENII syndromes [19].